Period Blocker®, Oral
YES! You can safely delay your period by taking this medicine.
- may be taken for 1 – 10 days
- keeps that special date on schedule!
- norethindrone is the active ingredient
- if any side effect, it would be pelvic fullness
- Vie has the correct dosing
We Also Recommend for You
Pink Again® Anal Bleach, Topical$66.00 Select options
notes; Period Blocker® is Vie’s prescription protocol to effectively delay your period. This method has been shown to be the MOST reliable and predictable. You may delay your period for up to 10 days. The only side-effect is a feeling of fullness in the pelvis, as you are holding your cycle just before the period. We do recommend you try this at a non-essential time just to familiarize with how your body reacts to this therapy.
This therapy does not constitute birth control during its use. You still must use a condom. If you do not use condoms, an alternate method to maintain birth control is to start a day 1 birth control pill pack and continue it straight on through the period blocking therapy.
Published: 28 May 2019
Norethindrone is superior to combined oral contraceptive pills in short-term delay of menses and onset of breakthrough bleeding: a randomized trial
Joshua Dean, Katherine J. Kramer, Fauzia Akbary, Shaunte Wade, Maik Hüttemann, Jay M. Berman & Maurice-Andre Recanati
BMC Women’s Health volume 19, Article number: 70 (2019)
To determine whether oral norethindrone acetate is superior to combined oral contraceptives (OCP) in delaying menstruation and preventing breakthrough bleeding when started late in the cycle.
This article comprises of a case control study followed by a pilot randomized controlled study. In the first study, four women who presented late in their cycle and desired avoiding vaginal bleeding within 10 days before a wedding were started on norethindrone 5 mg three times daily and
compared to age matched controls started on OCPs. Subsequently, a randomized controlled pilot study (n = 50) comparing OCPs to norethindrone for the retiming of menses was conducted. Percentage of women reporting spotting were compared with level of statistical significance set at p < 0.05.
Of the norethindrone treated group, only 2 women (8%) reported spotting compared with 10 women (43%) in the control group (p < 0.01).
Norethindrone recipients experienced significant weight gain, which resolved after cessation of therapy and had heavier withdrawal bleed (p < 0.04) when compared to controls. Patient satisfaction was significantly higher in the norethindrone group, with 80% willing to choose this method again. Time to conceive was significantly shorter in the norethindrone group (p < 0.03).
Norethindrone, begun on or before cycle day 12, is superior for women who desire to avoid breakthrough bleeding and maintain fertility when compared to OCPs. It is an ideal approach in patients presenting late in their cycle and who desire delaying menses as well as in circumstances when even minute amounts of breakthrough bleeding cannot be tolerated.